We recently published a list of 10 Stocks Investors Dumped Fast. In this article, we are going to take a look at where ...

Sarepta Therapeutics (NasdaqGS:SRPT) saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year.

Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector ...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta Therapeutics (SRPT) stock gains as Scotiabank upgrades it to Sector Outperform ting a compelling risk-reward setup. Read more here.

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million.

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics SRPT, and it's important for retail traders to take note. \This activity came to our attention today through ...

Analysts' ratings for Sarepta Therapeutics SRPT over the last quarter vary from bullish to bearish, as provided by 30 analysts. In the table below, you'll find a summary of their recent ratings ...